Trump budget would limit NIH grant recipients' spending on admin, IT

A cap could be placed on what “indirect” medical research costs can be covered by National Institutes of Health (NIH) grants, which researchers warn could “disembowel” their institutions.

As reported by The Atlantic, the Trump administration’s full budget, due out next week, could include a 10 percent cap on overhead costs like administration, equipment, libraries, IT, lighting, heating, electricity. HHS Secretary Tom Price, MD, has said such costs are evidence of “inefficiencies” in NIH, with some universities spending up to 85 percent of their grants on those costs, which are negotiated with the agency.

Those in the research field, however, say many of the costs aren’t optional and grants don’t always fund what it takes to keep labs and research facilities running.

“We could find efficiencies,” said Mary Woolley, president of Research!America, a non-profit that advocates for biomedical research, “but you’re not looking for efficiencies when you say we’ll cut off three or four of your appendages.”

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.